RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.69
−2.31%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.70
From 52W high−32.94%
Volume559143.00
Market cap$76.27M
P/E (TTM)—
P/S (TTM)38.6x
Div yield—
Key dataSep 18, 2026
Open
$1.70
From 52W high
−32.94%
Volume
559143.00
Market cap
$76.27M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.5x
P/E (TTM)
—
RSI (14)
51.0
MomentumView details →
1D Return
−2.31%
YTD Return
+100.57%
SummaryUpdated Jun 1, 2026
RenovoRx, Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Los Altos, California. The company went public in August 2021 and focuses on developing innovative therapies for treating solid tumors, particularly pancreatic cancer. RenovoRx has developed a unique approach combining drug delivery devices with chemotherapy medications to improve treatment outcomes while reducing side effects for cancer patients.
Similar companies
Latest newsMore news →
RenovoRx received written notification from Nasdaq confirming it regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.30d agoRenovoRx announced that its RenovoCath delivery device has expanded to 21 centers, indicating commercialization progress.35d agoRenovoRx delivered the first treatment with RenovoCath in a patient with sarcoma in a clinical setting, marking expansion of the device to other solid tumors.39d ago